Patents by Inventor Soren Moeller

Soren Moeller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230193018
    Abstract: A toy building element made of recycled Acrylonitrile Butadiene Styrene (“ABS”) material and manufactured by processing, of a resin comprising, mechanically recycled ABS polymers and/or chemically recycled ABS polymers recovered from a solvent dissolution recycling process. A method for the manufacture of a toy building element includes providing and screening an ABS waste material. The method includes recovering recycled ABS polymers from the screened ABS waste material by subjecting the ABS waste material to grinding and/or a solvent dissolution recycling process. The method includes obtaining a resin by mixing the recovered ABS polymers with one or more additive(s) and optionally one or more ABS polymers selected from the group consisting of virgin ABS polymers, chemically recycled ABS polymers recovered from pyrolysis and chemically recycled ABS polymers recovered from chemical depolymerisation. The method thereafter includes manufacturing the toy building element by processing the resin.
    Type: Application
    Filed: October 14, 2022
    Publication date: June 22, 2023
    Inventors: Søren KRISTIANSEN, Søren MØLLER-SØRENSEN, René MIKKELSEN, Bistra ANDERSEN, Emil ANDERSEN, Carina Gejl NIELSEN, Anders Christian JENSEN
  • Patent number: 10023912
    Abstract: An improved method of in situ hybridization which relies on an improved formulation of the in situ hybridization buffer is described. In at least some formulations the buffer are non-toxic. The combination of Locked Nucleic Acid (LNA) comprising ISH probes and the improved ISH buffer are useful for detection of small non-coding RNA as well as in the manufacturing of ISH kits directed to the detection of such small non-coding RNA. Further disclosed is a method of semi-quantitative ISH and demonstration of the semi-quantitative ISHs diagnostic potential.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: July 17, 2018
    Assignee: EXIQON A/S
    Inventors: Boye Schnack Nielsen, Stine Jørgensen, Jan Skouv, Adam Baker, Søren Møller
  • Publication number: 20160160278
    Abstract: An improved method of in situ hybridization which relies on an improved formulation of the in situ hybridization buffer is described. In at least some formulations the buffer are non-toxic. The combination of Locked Nucleic Acid (LNA) comprising ISH probes and the improved ISH buffer are useful for detection of small non-coding RNA as well as in the manufacturing of ISH kits directed to the detection of such small non-coding RNA. Further disclosed is a method of semi-quantitative ISH and demonstration of the semi-quantitative ISHs diagnostic potential.
    Type: Application
    Filed: December 4, 2015
    Publication date: June 9, 2016
    Inventors: Boye Schnack NIELSEN, Stine JØRGENSEN, Jan SKOUV, Adam BAKER, Søren MØLLER
  • Patent number: 9212390
    Abstract: An improved method of in situ hybridization which relies on an improved formulation of the in situ hybridization buffer is described. In at least some formulations the buffer are non-toxic. The combination of Locked Nucleic Acid (LNA) comprising ISH probes and the improved ISH buffer are useful for detection of small non-coding RNA as well as in the manufacturing of ISH kits directed to the detection of such small non-coding RNA. Further disclosed is a method of semi-quantitative ISH and demonstration of the semi-quantitative ISHs diagnostic potential.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: December 15, 2015
    Assignee: EXIQON A/S
    Inventors: Boye Schnack Nielsen, Stine Jørgensen, Jan Skouv, Adam Baker, Søren Møller
  • Publication number: 20130190499
    Abstract: The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.
    Type: Application
    Filed: March 11, 2011
    Publication date: July 25, 2013
    Applicant: H. Lundbeck A/S
    Inventors: Nikolay Khanzhin, Klaus Bæk Simonsen, Søren Møller Nielsen, Karsten Juhl
  • Publication number: 20130164750
    Abstract: An improved method of in situ hybridization which relies on an improved formulation of the in situ hybridization buffer is described. In at least some formulations the buffer are non-toxic. The combination of Locked Nucleic Acid (LNA) comprising ISH probes and the improved ISH buffer are useful for detection of small non-coding RNA as well as in the manufacturing of ISH kits directed to the detection of such small non-coding RNA. Further disclosed is a method of semi-quantitative ISH and demonstration of the semi-quantitative ISHs diagnostic potential.
    Type: Application
    Filed: April 28, 2011
    Publication date: June 27, 2013
    Applicant: EXIQON A/S
    Inventors: Boye Schnack Nielsen, Stine Jørgensen, Jan Skouv, Adam Baker, Søren Møller
  • Patent number: 8415356
    Abstract: Isoquinolone derivatives of the general formula I are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: April 9, 2013
    Assignee: H. Lundbeck A/S
    Inventors: Nikolay Khanzhin, Karsten Juhl, Søren Møller Nielsen, Klaus Bæk Simonsen
  • Publication number: 20120184603
    Abstract: The invention provides new sequences for human microRNAs associated with cancer which may be used as molecular markers for cancer diagnostics or as therapeutic targets or agents.
    Type: Application
    Filed: March 30, 2012
    Publication date: July 19, 2012
    Applicant: Exiqon A/S
    Inventors: Thomas Litman, Søren Møller, Søren Morgenthaler Echwald, Morten Lindow, Anders Martin Bøgild Jacobsen, Anders Stærmose Krogh, Sanne Nygaard, Rolf Søkilde
  • Patent number: 8221201
    Abstract: A ventilation device for ventilation of a building having a double-window construction with an air space. The device communicates with the open air space and has four throttles. The first and the second throttles can selectively cut off the passage of air from the air space into a first and a second chamber, respectively, of the device. The third throttle can selectively cut off the passage of air from the first chamber and into the building. The fourth throttle can selectively cut off the passage of air between the open air space and the first and the second chamber. Temperature-sensitive actuators can activate the throttles, selectively adjusting air flow.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: July 17, 2012
    Inventors: Poul Christensen, Jens Arboe Harild, Soren Møller Madsen, Niels Herskind
  • Patent number: 8207347
    Abstract: The present invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: June 26, 2012
    Assignee: H. Lundbeck A/S
    Inventors: Nikolay Khanzhin, Søren Møller Nielsen, Karsten Juhl, Lars Kyhn Rasmussen
  • Patent number: 8188255
    Abstract: The invention provides new sequences for human microRNAs associated with cancer which may be used as molecular markers for cancer diagnostics or as therapeutic targets or agents.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: May 29, 2012
    Assignee: Exiqon A/S
    Inventors: Thomas Litman, Søren Møller, Søren Morgenthaler Echwald, Morten Lindow, Anders Martin Bøgild Jacobsen, Anders Stærmose Krogh, Sanne Nygaard, Rolf Søkilde
  • Publication number: 20110224247
    Abstract: The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.
    Type: Application
    Filed: March 11, 2011
    Publication date: September 15, 2011
    Applicant: H. LUNDBECK A/S
    Inventors: Nikolay Khanzhin, Klaus Bæk Simonsen, Søren Møller Nielsen, Karsten Juhl
  • Publication number: 20110144164
    Abstract: The present invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.
    Type: Application
    Filed: December 14, 2010
    Publication date: June 16, 2011
    Applicant: H. LUNDBECK A/S
    Inventors: Nikolay Khanzhin, Søren Møller Nielsen, Karsten Juhl, Lars Kyhn Rasmussen
  • Publication number: 20110130407
    Abstract: Isoquinolone derivatives of the general formula I are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.
    Type: Application
    Filed: June 19, 2009
    Publication date: June 2, 2011
    Applicant: H. LUNDBECK A/S
    Inventors: Nikolay Khanzhin, Karsten Juhl, Søren Møller Nielsen, Klaus Baek Simonsen
  • Patent number: 7834008
    Abstract: The present invention relates to cyclopropyl derivatives of formula (I) and salt thereof. These compounds are NK3 receptor antagonists and may therefore be useful for treatment of diseases where the NK3 receptor is implicated, e.g. psychotic disorders.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: November 16, 2010
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Tore Hansen, Anders Poulsen, Berith Bjørnholm, Thomas Ruhland, Morten Bang Nørgaard, Søren Møller Nielsen
  • Publication number: 20100286044
    Abstract: Disclosed is a method for determining the cellular or tissue origin of tumor cells. The method entails determining the presence of at least one micro RNA (miRNA) in a sample derived from tumor tissue and based on the said determination establishing a miRNA expression profile and comparing this with pre-established miRNA expression profiles from cells, tissues or tumors. The determination uses short oligonucleotide probes comprising modified affinity-enhancing nucleobases.
    Type: Application
    Filed: December 29, 2006
    Publication date: November 11, 2010
    Applicant: Exiqon A/S
    Inventors: Thomas Litman, Søren Møller, Søren Morgenthaler Echwald, Nana Jacobsen, Christian Glue
  • Patent number: 7273745
    Abstract: The present invention relates to pectate lyases comprising the amino acid sequence Asn Leu Asn Ser Arg Val Pro (NLNSRVP) (amino acids 236-242 of SEQ ID NO: 2) belonging to Family 1 of polysaccharide lyases have good performance in industrial processes under neutral or alkaline conditions such as laundering and textile processing. The pectate lyase may be derivable from Bacillus species.
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: September 25, 2007
    Assignee: Novozymes A/S
    Inventors: Lene Nonboe Andersen, Hanne Dela, legal representative, Niels Erik Krebs Lange, Mads Eskelund Bjørnvad, Søren Møller, Sanne O. Schrøder Glad, Markus Sakari Kauppinen, Kirk Schnorr, Lars Kongsbak, Martin Schülein, deceased
  • Patent number: 6846505
    Abstract: The present invention provides an anti-oxidant composition comprising a cyclic compound having formula I or a derivative thereof, wherein R1 and R2 are indepednetly selected from —OH, ?O, wherein R3 is a substituent comprising an —OH group; and wherein R4 and R5 are other than H; with the proviso that the compound is other than ascorbic acid.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: January 25, 2005
    Assignee: Danisco A/S
    Inventors: Søren Møller Andersen, Torben Isak, Henrik Max Jensen, Jan Marcussen, Shukun Yu
  • Patent number: 6677147
    Abstract: The present invention relates to pectate lyases comprising the amino acid sequence Asn Leu Asn Ser Arg Val Pro (NLNSRVP) (SEQ ID NO: 2) belonging to Family 1 of polysaccharide lyases have good performance in industrial processes under neutral or alkaline conditions such as laundering and textile processing. The pectate lyase may be derivable from Bacillus species.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: January 13, 2004
    Assignee: Novozymes A/S
    Inventors: Lene Nonboe Andersen, Martin Schülein, Niels Erik Krebs Lange, Mads Eskelund Bjørnvad, Søren Møller, Sanne O. Schroder Glad, Markus Sakari Kauppinen, Kirk Schnorr, Lars Kongsbak
  • Patent number: 6368843
    Abstract: A novel group of pectate lyases comprising the amino acid sequence Asn Leu Asn Ser Arg Val Pro (NLNSRVP) belonging to Family 1 of polysaccharide lyases have good performance in industrial processes under neutral or alkaline conditions such as laundering and textile processing. The pectate lyase may be derivable from Bacillus species.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: April 9, 2002
    Assignee: Novozymes A/S
    Inventors: Lene Nonboe Andersen, Martin Schülein, Niels Erik Krebs Lange, Mads Eskelund Bjørnvad, Søren Møller, Sanne O. Schrøder Glad, Markus Sakari Kauppinen, Kirk Schnorr, Lars Kongsbak